RIGL SEC Filings: 8-K, 10-Q, S-3 & 424B

Financials

TYPE

HEADLINE

FILED AT

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Nov 5, 2026

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Aug 4, 2026

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

May 5, 2026

10-K

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]

Mar 3, 2026

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Nov 4, 2025

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Aug 5, 2025

News

TYPE

HEADLINE

FILED AT

8-K

Rigel Reports Third Quarter 2026 Financial Results and Provides Business Update

Nov 5, 2026

8-K

Rigel Pharmaceuticals Reports Second Quarter 2026 Financial Results and Strategic Portfolio Expansion

Aug 4, 2026

8-K

Rigel Pharmaceuticals Announces Leadership Transition in Chief Medical Officer Role

Jul 1, 2026

8-K

Rigel Pharmaceuticals Completes Licensing Agreement for VEPPANU™ (vepdegestrant)

Jun 17, 2026

8-K

Rigel Pharmaceuticals, Inc. Announces Results of 2026 Annual Meeting of Stockholders

May 20, 2026

8-K

Rigel Pharmaceuticals Enters Exclusive Worldwide Licensing Agreement for VEPPANU™ (vepdegestrant)

May 12, 2026

Prospectus

TYPE

HEADLINE

FILED AT

424B5

$200,000,000 Common Stock Preferred Stock Debt Securities Warrants

Aug 4, 2020

424B5

16,000,000 Shares

Apr 20, 2018

424B5

15,000,000 Shares

Apr 18, 2018

424B5

18,100,000 Shares

Oct 5, 2017

424B5

$150,000,000 Common Stock Preferred Stock Debt Securities Warrants

Oct 3, 2017

424B5

Up to $40,000,000 of Shares

May 30, 2017

Registrations

TYPE

HEADLINE

FILED AT

S-8

Form S-8 - Securities to be offered to employees in employee benefit plans

Aug 4, 2026

S-8

Form S-8 - Securities to be offered to employees in employee benefit plans

Aug 6, 2025

S-8

Form S-8 - Securities to be offered to employees in employee benefit plans

Aug 6, 2024

S-3

SHELF | ATM | Offering amount: $250,000,000.00 EFFECTIVE

Aug 2, 2024

S-8

Registration

Aug 1, 2023

S-8

Registration

Mar 7, 2023

Proxies

TYPE

HEADLINE

FILED AT

DEFA14A

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Apr 3, 2026

DEF 14A

Form DEF 14A - Other definitive proxy statements

Apr 3, 2026

DEFA14A

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Apr 10, 2025

DEF 14A

Form DEF 14A - Other definitive proxy statements

Apr 10, 2025

DEFA14A

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Apr 10, 2024

DEF 14A

Form DEF 14A - Other definitive proxy statements

Apr 10, 2024

Ownerships

TYPE

HEADLINE

FILED AT

Schorno Dean L (Reporting)

Sep 3, 2026

Santos David A (Reporting)

Sep 3, 2026

RODRIGUEZ RAUL R (Reporting)

Sep 3, 2026

Furey Raymond J. (Reporting)

Sep 3, 2026

SCHEDULE 13G/A

ARMISTICE CAPITAL, LLC (Filed by)

Aug 14, 2026

SCHEDULE 13G/A

Soleus Capital Master Fund, L.P. (Filed by)

Aug 13, 2026

Other

TYPE

HEADLINE

FILED AT

EFFECT

Form EFFECT - Notice of Effectiveness

Aug 12, 2024

CORRESP

Form CORRESP - Correspondence

Aug 8, 2024

LETTER

Form UPLOAD - SEC-generated letter

Aug 7, 2024

EFFECT

Form EFFECT - Notice of Effectiveness

May 4, 2022

CT ORDER

Form CT ORDER - Confidential treatment order

Apr 24, 2020

CT ORDER

Form CT ORDER - Confidential treatment order

Apr 24, 2020

Rigel Pharmaceuticals, Inc. RIGL · SEC Filings